Lupin is currently trading at Rs. 2342.30, up by 10.55 points or 0.45% from its previous closing of Rs. 2331.75 on the BSE.

The scrip opened at Rs. 2340.00 and has touched a high and low of Rs. 2354.70 and Rs. 2331.75 respectively. So far 4642 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2376.00 on 11-Mar-2026 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 2354.70 and Rs. 2242.00 respectively. The current market cap of the company is Rs. 107258.79 crore.

The promoters holding in the company stood at 46.89%, while Institutions and Non-Institutions held 47.07% and 6.03% respectively.

Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45mg and 17.8mg. This product would be manufactured at Lupin’s Nagpur facility in India.

The USFDA has tentatively approved Lupin’s Pitolisant Tablets 4.45mg and 17.8 mg as bioequivalent to Wakix for the indication in the approved labeling.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.